Table 5 List of most significant SNPs in the CCV analysis for BRCA1 mutation carriers.

From: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Fine mapping regiona

Signalb

#CCVc

Location

SNP named

Chre

Positionf

Nearest gene

Localisation

Estimated effect allele

Referent Allele

Frequency g

r² h

Pi

ORj

PERk

ORl

PCIMBAm

HRCIMBAn

chr11:46773616-47773616

1

74

11p11.2

rs60882887

11

47475675

RAPSN, CELF1

Intergenic

A

G

0.14

0.95

2.20e−10

0.82

3.20e−06

0.82

7.00e−01

0.99

chr17:39141815-40141815

1

2

17q21.2

rs5820435

17

39961558

LEPREL4

Intronic

A

C

0.45

0.51

1.10e−11

0.82

2.80e−05

0.85

9.10e−01

1.00

2

2

17q21.2

rs7222250

17

39938469

JUP

Intronic

C

T

0.44

0.66

5.50e−14

1.23

3.90e−07

1.20

8.70e−01

1.00

3

6

17q21.2

rs9901834

17

39926811

JUP

Intronic

A

G

0.10

0.55

7.20e−10

0.72

3.90e−06

0.72

7.40e−01

1.02

4

3

17q21.2

rs58117746

17

39305775

KRTAP4-5

Intronic

TGGCAGCAGCTGGGGC

T

0.39

0.60

5.50e−09

1.17

4.60e−04

1.13

2.20e−02

1.06

5

13

17q21.2

rs2239711

17

39633317

KRT35

Intronic

A

G

0.29

0.93

4.90e−11

0.85

2.90e−04

0.88

5.00e−01

0.98

6

4

17q21.2

rs10708222

17

40137437

DNAJC7

Intronic

T

TA

0.17

0.60

8.40e−07

1.18

6.10e−04

1.17

2.28e−01

0.95

7

4

17q21.2

rs41283425

17

39925713

JUP

Intronic

T

C

0.06

0.54

4.30e−07

0.73

1.30e−05

0.69

4.82e−01

0.95

8

15

17q21.2

rs56291217

17

39858199

JUP

Intronic

AT

A

0.44

0.76

6.70e−08

0.88

1.20e−06

0.85

4.06e−01

1.03

9

1

17q21.2

rs111637825

17

40134782

DNAJC7

Intronic

A

G

0.06

0.89

3.60e−07

0.74

3.50e−04

0.75

4.47e−01

0.96

  1. N = 67,469 breast cancer cases (60,212 BCAC cases and 7,257 BRCA1 mutation carrier cases).
  2. aSignificant region in the main analysis used to look for credible causal variants (CCV).
  3. bSignal number (the first one corresponds to the CCV set without any adjustment and the following are those with adjustment on each most significant SNP of the previous signals).
  4. cNumber of credible causal variants at each signal (SNP with p-value at 2 order of magnitude of the most significant one).
  5. dThe most significant SNP after adjustment on the most significant SNPs of the previous signals (except for these of the signal 1).
  6. eChromosome.
  7. fBuild 37 position.
  8. gFrequency of the allele for which effect is estimated in BCAC cases (OncoArray dataset).
  9. hImputation accuracy.
  10. ip-value in the case-only analysis after adjustment on the most significant SNPs of the previous signals (except for these of the signal 1).
  11. jPer allele odds ratio estimated in the case-only analysis. OR values were computed from a two sided logistic regression using a 1df lrtest adjusted for age at BC diagnosis, country, the first four principal components and the most significant SNPs of the previous signals (except for these of the signal 1).
  12. kP-value in the case-only analysis restricted to ER-negative BCAC cases and after adjustment with the most significant SNP of the previous signals (except for these of the signal 1).
  13. lPer allele odds ratio estimated in the case-only analysis restricted to ER-negative BCAC cases and after adjustment with the most significant SNP of the previous signals (except for these of the signal 1).
  14. mp-value found in CIMBA cohort analysis.
  15. n Per allele hazard ratio estimated in CIMBA cohort analysis.